ClinicalTrials.gg
CompletedNCT01907776Updated Jun 12, 2014

Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers

A Phase 1 interventional study of ME1100 inhalation solution and ME1100 placebo inhalation solution in Healthy, sponsored by Meiji Seika Pharma Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-12.

Sponsored by Meiji Seika Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a single-center, randomized, double-blind, placebo-controlled, sequential group study. The primary objective of this study is to assess the tolerability and safety of single doses of ME1100 inhalation solution (orally inhaled arbekacin). The secondary objective is to determine the systemic exposure to, and urinary elimination of, ME1100.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Meiji Seika Pharma Co., Ltd. is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male (who are surgically sterile or agree to practice barrier throughout their participation in the study) or Female (using oral or double barrier contraceptive if sexually active, surgically sterile or confirmed by follicle stimulation hormone test);
  • Willing to give written
  • 18 to 55 years of age at time of consent
  • of 18-30 kg/m2
  • Non-smoker (for at least 6 months prior to screening) and willing to abstain from smoking during the course of the study
  • Good general health as determined by medical history, physical examination, 12-lead and clinical laboratory tests (including normal renal function and high frequency audiometry)
  • Willing to abstain from alcohol, caffeine, and xanthine-containing beverages for 24 hours prior to and 72 hours after dosing.
  • Japanese subjects must be first generation Japanese (4 grandparents, biologic parents and subject born in Japan)

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled, disease which in the opinion of the Principal Investigator or Medical Monitor would place the subject at risk through study participation or would confound the assessment of the safety of ME1100 inhalation solution
  • Evidence of current or history of respiratory disease, including asthma, emphysema, chronic bronchitis, or cystic fibrosis
  • History or current symptom(s) of respiratory tract inflammation within 30 days of Visit 2
  • History of hearing, balance or ear disorder or surgery or injury to the ears, or with genetic mutation (>5.0% heteroplasmy) suggestive of increased risk of hearing loss (MT-RNR1 [A1555G] for mitochondrial 12S ribosomal RNA gene or MT-TS1 [A3243G] for mitochondrial transfer RNA serine 1)
  • History of parent, sibling or parental sibling reporting hearing loss before age 65 years
  • History of
  • History of clinically significant alcohol or drug abuse
  • History within last 6 months or current use of any tobacco product including e-cigarettes
  • Positive drug screen for drugs of abuse
  • Positive test for , or
  • Use of any prescription or over-the-counter medications (except oral or hormonal ), herbal supplements, or vitamins within 14 days of Visit 2
  • Known to any aminoglycoside or bacitracin antibiotic
  • Female of with a positive urine pregnancy test, or currently breast feeding.
  • Inability to perform reproducible spirometry in accordance with American Thoracic Society (ATS) guidelines
  • Abnormal (FEV1), Forced Vital Capacity (FVC), or FEV1/FVC (FEV1 or FVC \< 80% of predicted or FEV1/FVC ratio \< 0.7)
  • FEV1 variability > 10% between Visit 1 and Visit 2 (prior to dosing)
  • Significant blood donation (or testing) in previous 8 weeks before screening.
  • Use of any Product in previous 30 days or 5 half-lives, whichever is longer, preceding start of screening.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    ME1100

    ME1100 inhalation solution (arbekacin for oral inhalation at 150 mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose

    Drug: ME1100 inhalation solution

  • Placebo comparator
    Placebo

    ME1100 placebo inhalation solution

    Drug: ME1100 placebo inhalation solution

Interventions

  • DrugArbekacinStudies of ArbekacinArbekacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose

    Also known as: arbekacin, ME1100

  • DrugME1100 placebo inhalation solution

    Vehicle placebo

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    Time frame: from Baseline to Day 8-10

  2. Number of participants with abnormal physical examinations

    Time frame: from Baseline to Day 8-10

  3. Number of participants with abnormal 12-lead electrocardiograms

    Time frame: from Baseline to Day 8-10

  4. Number of participants with abnormal vital signs

    Time frame: from Baseline to Day 8-10

  5. Number of participants with abnormal safety laboratory measurements

    Time frame: from Baseline to Day 8-10

Secondary outcomes

  1. Serum Concentration of ME1100

    Time frame: 5, 15, 30 minutes and 1, 2, 3, 4, 6, 8, 12, 18 and 24 hours post START of dosing

  2. Urinary elimination of ME1100

    Time frame: 0-6, 6-12, 12-24, 24-48 and 48-72 hours after single dosing

07

Study locations

1 site
  • WCCT Global, LLC
    Cypress, California, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013 and a primary completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2013
First posted
Jul 25, 2013
Start
Jul 2013
Primary completionActual
Dec 2013
Last update
Jun 12, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01907776
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Responsible party
Sponsor
First posted
Jul 25, 2013
Start date
Jul 2013
Primary completion
Dec 2013
Last update
Jun 12, 2014

Study contacts

Mitsuharu Egawa
study chair · Meiji Seika Pharma Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arbekacin

Start the discussion